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Abstract Background: Energy
deﬁcit is a common and serious
problem in intensive care units and is
associated with increased rates of
complications, length of stay, and
mortality. Parenteral nutrition (PN),
either alone or in combination with
enteral nutrition, can improve nutrient
delivery to critically ill patients. Lip-
ids provide a key source of calories
within PN formulations, preventing or
correcting energy deﬁcits and
improving outcomes. Discus-
sion: In this article, we review the
role of parenteral lipid emulsions
(LEs) in the management of critically
ill patients and highlight important
biologic activities associated with
lipids. Soybean-oil-based LEs with
high contents of polyunsaturated fatty
acids (PUFA) were the ﬁrst widely
used formulations in the intensive
care setting. However, they may be
associated with increased rates of
infection and lipid peroxidation,
which can exacerbate oxidative
stress. More recently developed
parenteral LEs employ partial substi-
tution of soybean oil with oils
providing medium-chain triglycer-
ides, x-9 monounsaturated fatty acids
or x-3 PUFA. Many of these LEs
have demonstrated reduced effects on
oxidative stress, immune responses,
and inﬂammation. However, the
effects of these LEs on clinical
outcomes have not been extensively
evaluated. Conclusions: Ongoing
research using adequately designed
and well-controlled studies that char-
acterize the biologic properties of
LEs should assist clinicians in
selecting LEs within the critical care
setting. Prescription of PN containing
LEs should be based on available
clinical data, while considering the
individual patient’s physiologic
proﬁle and therapeutic requirements.
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Introduction
Many critically ill patients admitted to the intensive care
unit (ICU) enter a state of negative energy balance during
the ﬁrst 3–4 days following admission [1, 2]. This energy
deﬁcit often progresses during their ICU stay and may
result in malnutrition and adverse outcomes [1]. Multiple
factors contribute to energy deﬁcit, including increased
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DOI 10.1007/s00134-009-1744-5 REVIEWmetabolism [3, 4], delays in the initiation of feeding, and
inadequate caloric provision [1]. Indeed, a number of
studies have demonstrated that target caloric intake is
achieved in only 50–75% of ICU patients and that as
many as 25% of patients receive only 1,000–1,500 kcal/
day [5].
Prolonged negative energy balance within the ICU is
associated with serious complications [1, 2]. In two sep-
arate studies, progressive negative energy balance was
strongly correlated with increased numbers of infectious
complications, particularly sepsis [1, 2]. In addition,
cumulative total energy deﬁcit has been correlated with
increased length of mechanical ventilation, length of ICU
stay, total number of complications, and duration of
antibiotic use [1]. Delayed initiation of feeding and/or
negative energy balance in critical care patients may also
be associated with higher ICU and in-hospital mortality
rates [5, 6], while early initiation of feeding results in
improved caloric intake [7].
This article aims to review well-known papers that
evaluate potential biologic effects of lipids when provided
as a parenteral energy source and to provide future per-
spectives on the use of parenteral lipid emulsions (LEs) in
critically ill patients.
Role of parenteral nutrition in the intensive care
setting
Given the association between negative energy balance/
malnutrition and both morbidity and mortality, ensuring
that critically ill patients receive adequate caloric and
nutrient intake should be a high priority for intensive
care clinicians. Current guidelines recommend that all
ICU patients who tolerate enteral nutrition (EN) should
receive EN (approximately 25–30 kcal/kg per day) if
they are not expected to be on a full oral diet within
3 days [8]. However, within the ICU setting EN may
not be feasible or cannot be established at rates that
provide adequate nutrition for a number of reasons. For
example, EN may be frequently interrupted because of
diagnostic investigations, surgery, diarrhea, vomiting,
mechanical problems (e.g., tube displacement) or patient
transfers [9]. EN may be contraindicated in patients with
anatomic gastrointestinal disorders, severe diarrhea, and
reduced intestinal blood ﬂow [10]. Parenteral nutrition
(PN) is therefore recommended under certain circum-
stances (Table 1)[ 11].
Despitetheserecommendations,PNisoftenunderused.
Although PN was once a popular means of administering
nutrients, utilization has decreased in recent years because
of concerns regarding metabolic complications associated
with overfeeding [12, 13] and an increased risk of septic
complications[8].IthasbeensuggestedthatENisrequired
in order to maintain gut function and is less likely to cause
bacterial translocation than PN, although other perspec-
tives exist [12, 14]. However, available literature suggests
that supplementation of EN with PN enhances caloric
intakeand nutritionalstatus[1,15]andthatPNisassafeas
EN in critically ill patients [16, 17].
Individualizing nutrition in critically ill patients
The systemic inﬂammatory response is associated with
metabolic stress in critically ill patients, including an
overall increase in metabolic rate, production of reactive
species, insulin resistance, and alterations in substrate uti-
lization that result in hyperglycemia (partly because of
increased gluconeogenesis), lipolysis, and increased pro-
teolysis relative to protein synthesis, potentially resulting
innegativenitrogenbalance[3,4,11,18,19].Thenutrition
providedtopatientswithintheICUsettingshouldtherefore
aim to blunt this catabolic state and enhance anabolic
activity during recovery while avoiding overfeeding.
Administration of dextrose must often be balanced with
infusion of insulin to maintain euglycemia and minimize
increasesincarbondioxide(CO2)production.Aminoacids
are required to promote nitrogen retention and support
proteinsynthesis [10].Lipidsare generallyadministeredto
provide 30% of total calories, but dosage reduction should
be considered when triglyceride concentrations are
[400 mg/dL [15]. Nutritional requirements vary depend-
ing upon the level of metabolic stress; therefore, energy
requirements, as well as blood glucose and electrolyte
concentrations, should be monitored on a daily basis, and
the composition of artiﬁcial nutrition adjusted as required
[15].
Table 1 Potential indications
for parenteral nutrition in
intensive care patients [8–10]
Parenteral nutrition as a
supplement to enteral nutrition
Parenteral
nutrition alone
Enteral nutrition is insufﬁcient to meet
target caloric intake
Intolerance to enteral nutrition
Suppression of gastrointestinal activity
(e.g., immediately following injury or
surgery)
Major gut failure (e.g., extensive intestinal
resection)
Conditions preventing adequate nutrient
absorption (e.g., inﬂammatory bowel disease,
gastric outlet obstruction, intractable vomiting,
severe diarrhea, paralytic ileus)
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Early PN formulations consisted primarily of high con-
centrations of glucose and amino acids in order to provide
adequate calories [20] and were often associated with a
number of complications. Prolonged use of these formu-
lations was associated with essential fatty acid (EFA)
deﬁciency because they did not provide linoleic acid (LA;
18:2x-6) or a-linolenic acid (ALA; 18:3x-3), which are
not synthesized by the body and must be obtained from
the diet [20–22]. Furthermore, the high dextrose loads
provided by early PN solutions were associated with a
variety of other complications, such as excessive CO2
production, metabolic stress (increased concentrations of
cortisol, epinephrine, and glucagon), fever, and hepatic
steatosis [20]. As critical illnesses can be associated with
impaired glucose tolerance, overzealous infusion of
hypertonic dextrose solutions was often also associated
with hyperglycemia, which, if undetected and untreated,
can progress to hyperosmolar nonketotic coma [23].
Hyperglycemia can also be associated with an increased
incidence of complications in critically ill patients, such
as severe infections, multiple organ failure, and increased
mortality rates [24].
The incorporation of lipids into PN formulations has
addressed many of these issues. Lipids provide a more
energy-dense source of calories (approximately 9 kcal/
g) than either amino acids (4 kcal/g) or dextrose
monohydrate (3.4 kcal/g) [22]. Therefore, the ﬂuid
volume of PN required to achieve adequate caloric
intake can be substantially reduced. The reduced ﬂuid
volume and increase in osmolarity of formulations
incorporating LEs permit the safe administration of PN
via the peripheral and central routes. Formulations with
osmolarities B900 mOsm/L can be administered
peripherally, while highly osmolar formulations can be
administered via central veins, which may be of
importance in critically ill patients requiring ﬂuid
restriction [10, 25]. Currently available parenteral LEs
also contain sufﬁcient LA and ALA to prevent EFA
deﬁciency [21]. Perhaps most importantly, the use of
LEs in PN is associated with a reduction in the meta-
bolic complications related to excessive hypertonic
glucose infusion because the dextrose load is corre-
spondingly reduced. Results of a study involving
critically ill patients with gastric carcinoma, sepsis,
colitis or pancreatitis demonstrated that replacement of
one-third of the total calories contained in a conven-
tional glucose-amino acid PN formulation with a LE
maintained or increased patients’ body weight [26].
Plasma glucose concentrations were maintained or
reduced, and no cases of hyperglycemia, hyperosmolar
nonketotic coma or hypertriglyceridemia were observed
[26]. Another study found that ICU patients receiving
parenteral ﬂuids unintentionally received 150–600 kcal/
day dextrose as a constituent of various ﬂuids and drugs
[1]. Therefore, the administration of PN containing
LEs may help to prevent hyperglycemia and its
complications.
It should be noted that, despite the potential beneﬁts of
parenteral lipids, the use of LEs may be limited in some
patients. Triglycerides and other components of LEs form
artiﬁcial chylomicrons, which are hydrolyzed in the body
into free fatty acids (FA) and small remnant particles
taken up by the liver [22, 27, 28]; the presence of excess
phospholipids can also form liposomes, which interfere
with lipid metabolism and may result in hypercholester-
olemia [21, 22, 28]. When parenteral lipids are given in
excess of the liver’s ability to process them, hyperlipid-
emia and hepatic steatosis may occur [21, 22, 28].
Parenteral LEs also commonly contain phytosterols,
which may be present in the circulation in quantities large
enough to induce cholestasis [28]. Although hepatic
impairment is most common among patients on long-term
PN [28, 29], critically ill patients are also at increased risk
because plasma levels of FA increase with metabolic
stress [27, 30]. Therefore, parenteral LEs should be used
with caution in septic patients [27, 28, 30] and patients
with other conditions known to impair hepatic clearance
of FA [28, 30]. In addition to the duration and dose of
parenteral LEs and the patient’s level of metabolic stress,
the oil source of the LE may also affect the relative risk of
developing abnormal liver function [21, 22, 28, 31].
Evolution of parenteral lipid emulsions
Fatty acids
Although LEs contain numerous biologically active
compounds, triacylglycerols providing FA are their pri-
mary component. Fatty acids are classiﬁed according to
their structure, in terms of their hydrocarbon chain length
(short, medium or long), degree of saturation (number of
double bonds), and location of double bonds (counted
from the methyl carbon of the hydrocarbon chain)
(Table 2)[ 21, 22, 32]. Fatty acids play key roles in
determining the structural integrity and ﬂuidity of cell
membranes and can give rise to several important bio-
active mediators [21, 22, 33]. They can also regulate the
expression of a variety of genes and modulate cell sig-
naling pathways, such as those involved in apoptosis,
inﬂammation, and cell-mediated immune responses. For
example, longer-chain FA, such as arachidonic acid (AA;
20:4x-6), eicosapentaenoic acid (EPA; 20:5x-3), and
docosahexaenoic acid (DHA; 22:6x-3), are involved in
the generation of pro- and anti-inﬂammatory lipid medi-
ators [22].
737Early parenteral lipid emulsions
The majority of early LEs, which were ﬁrst included in
PN during the 1960s, were derived from soybean oil,
which contains a high concentration of both LA and
ALA [21, 22, 33]. These early LEs were demonstrated to
efﬁciently deliver nonglucose energy, thereby reducing
the adverse effects associated with intake of high dex-
trose concentrations [21]. Furthermore, they provided
EFA and the fat-soluble vitamins E and K [33]. How-
ever, studies published during the 1970s and 1980s
found that soybean-oil- and cottonseed-oil-based LEs
were associated with a number of adverse immunolog-
ical effects, such as reduced migration and phagocytosis
of granulocytes, which resulted in increased rates of
infections, including sepsis [34–37]. The cottonseed-oil-
based LE (Lipomul) had such adverse clinical effects
(e.g., hemolytic anemia) that it has since been removed
from the market.
Minimization of risks associated with parenteral lipids
in critical care patients
In an effort to address concerns associated with the soy-
bean-oil-based LEs, alternative sources of FA were
investigated [21]. Much of this research focused on
minimizing complications to which critically ill patients
are particularly susceptible, including oxidative stress,
alterations in cell-mediated immunity, inﬂammation, and
thrombosis. Although these are important issues to con-
sider, well-controlled clinical data in critically ill patients
are limited, and discrepancies may be observed between
studies because of the heterogeneity of the study designs,
patient populations, and speciﬁc LEs used.
Oxidative stress
Reactive oxygen species (ROS) can react with and dam-
age cell membranes, lipids, proteins, and DNA through
oxidation. Under normal circumstances, ROS may be
produced in increased amounts by cells such as neutro-
phils and macrophages as part of a natural immune
response. Levels of ROS are balanced by the neutralizing
activity of antioxidant molecules and enzymes, thereby
preventing excessive damage to the host [38, 39].
Oxidative stress occurs when an imbalance develops
because of high ROS levels and/or low antioxidant levels.
During critical illness, increased ROS and inﬂammatory
mediator production occurs against a background of
compromised antioxidant activity, which is partly due to
preexisting nutritional deﬁciencies and/or suboptimal
provision of artiﬁcial nutrition. Depletion of the antioxi-
dants selenium and zinc has been observed in trauma and
burn patients, while surgery is associated with reductions
in vitamins A, C, and E. This state of imbalance can cause
tissue damage and may play an important role in the
development of sepsis and multiple organ failure, among
other complications (Table 3)[ 38, 39].
A key consequence of oxidative stress is lipid perox-
idation, where ROS react with the double bond of
unsaturated lipids, producing unstable lipid peroxides that
may cause cell death [38, 39]. The high number of double
bonds present in x-6 and x-3 polyunsaturated fatty acids
(PUFA) provide targets for lipid peroxidation, and these
FA may therefore be associated with an increased risk of
oxidative stress [40]. For this reason, the antioxidant
a-tocopherol (vitamin E) is sometimes added to PUFA-
rich LEs in clinical practice.
Another approach to minimize oxidative stress is the
partial replacement of PUFA-rich oils with alternative FA
Table 2 Fatty acid nomenclature and key dietary sources [22, 32]
Common name Chemical name Chemical structure
[length of hydrocarbon
chain (C atoms): number
of double bonds and position
of ﬁrst double bond]
Dietary sources
Capric Decanoic 10:0 Coconut oil
Lauric Dodecanoic 12:0 Coconut oil
Myristic Tetradecanoic 14:0 Milk
Palmitic Hexadecanoic 16:0 Milk, eggs, animal fats, meat, cocoa butter,
palm oil, ﬁsh and ﬁsh oils
Palmitoleic 9-Hexadecenoic 16:1x-7 Fish and ﬁsh oils
Stearic Octadecanoic 18:0 Milk, eggs, animal fats, meat, cocoa butter
Oleic 9-Octadecenoic 18:1x-9 Milk, eggs, animal fats, meat, cocoa butter, olive oil
Linoleic 9,12-Octadecadienoic 18:2x-6 Seeds, seed oils, eggs, animal fats, meat
Arachidonic 5,8,11,14-Eicosatetraenoic 20:4x-6 Meat, egg lipids, algal oils
a-Linolenic 9,12,15-Octadecatrienoic 18:3x-3 Seeds, seed oils, green leaves, nuts
Eicosapentaenoic 5,8,11,14,17-Eicosapentaenoic 20:5x-3 Fish and ﬁsh oils
Docosapentaenoic 7,10,13,16,19-Docosapentaenoic 22:5x-3 Fish and ﬁsh oils
Docosahexaenoic 4,7,10,13,16,19-
Docosahexaenoic
22:6x-3 Fish and ﬁsh oils, algal oils
738sources, such as oils rich in medium-chain triglycerides
(MCT; derived from coconut oil containing medium-
chain FA such as capric acid), which are more resistant to
oxidative damage [41]. In one study of adults requiring
PN, a 1:1 mixture of MCT (derived from coconut oil) and
soybean oil (MCT/soybean oil LE) supplemented with a-
tocopherol demonstrated a reduced propensity to lipid
peroxidation when compared with a conventional soy-
bean-oil-based LE (Table 4)[ 42]. However, a separate
study comparing a soybean-oil-based LE with a MCT/
soybean oil LE supplemented with a-tocopherol in
patients undergoing abdominal surgery found no differ-
ence in lipid peroxidation between the two LEs [43].
Metabolism of MCT differs from that of long-chain
triglycerides (LCT). Unlike longer-chain FA, MCT
require little carnitine for mitochondrial entry, and it has
been suggested that their more rapid breakdown may
impart an increased production of ketones in critically ill
patients [44]. However, this is thought to be a transient
phenomenon that is reversible upon discontinuation of
MCT infusion and rarely causes clinical problems.
However, formulations containing MCT should not be
used in patients who develop ketosis or acidosis in the
ICU setting [41].
It has been suggested that monounsaturated FA
(MUFA; often derived from olive oil, which also provides
antioxidants) with only one double bond, such as oleic
acid (OA; 18:1x-9), may be less susceptible to lipid
peroxidation than x-6 and x-3 PUFA with several double
bonds. In vitro studies indicated that cells treated with
OA or olive oil were associated with less mitochondrial
ROS production than cells treated with certain PUFA
(e.g., DHA) or a soybean-oil-based LE [45, 46]. In a
preclinical rodent study, lipid peroxidation was lower
among mice administered OA or olive oil by gavage than
among mice administered PUFA (i.e., LA or DHA) or ﬁsh
oil [47]. In children requiring PN, a LE containing 80%
olive oil led to lower concentrations of certain lipid per-
oxides than a soybean-oil-based LE (Table 4)[ 48]. In a
separate study involving preterm infants, peroxidation
markers were similar between an olive-oil-rich LE
supplemented with a-tocopherol and a conventional
soybean-oil-based LE, whereas vitamin E status was
enhanced with olive-oil-rich LE [49].
Cell-mediated immunity
Fatty acids have been shown to modulate the immune
system in a number of ways, inﬂuencing cell signaling,
gene expression, and apoptosis. In particular, x-6 PUFA
have been associated with reduced migration and phag-
ocytic activity of neutrophils and macrophages,
decreased lymphocyte reactivity to microbial antigens,
and inhibition of antibody-dependent cellular cytotoxic-
ity [34, 35, 50–52]. The consequences of these
immunosuppressive actions have been demonstrated
within the ICU setting. When compared with PN con-
taining no lipids administered to trauma patients, PN
containing a soybean-oil-based LE was associated with
higher rates of infection and signiﬁcantly longer durations
of mechanical ventilation, longer ICU stays, and longer
hospital stays (Table 4)[ 53]. In patients with septic
shock, those receiving a soybean-oil-based LE showed
increased leukocyte counts and reduced neutrophil cyto-
toxic activity, while those receiving a ﬁsh-oil-based LE
experienced opposite effects [54]. However, excessive
(hypercaloric) feeding may also have contributed to
immunosuppression observed in some older studies.
Among surgical patients receiving PN, a soybean-oil-
based LE supplemented with ﬁsh oil was associated with
a shorter ICU and overall hospital stay when compared
with a LE that did not contain ﬁsh oil; however, the rates
of infection were similar between groups (Table 4)[ 55].
When a soybean-oil-based LE was supplemented with
ﬁsh oil, higher doses were associated with a reduction in
the length of ICU and overall hospital stay, signiﬁcantly
reduced antibiotic requirement, and signiﬁcantly
increased survival [56].
In comparison with soybean oil, MCT are generally
described as immune neutral; however, effects upon cer-
tain components of the immune system have been
described. In two ex vivo studies, MCT and MCT/soy-
bean oil LEs increased monocyte activation and
neutrophil adhesion and degranulation [57, 58]. In con-
trast, another ex vivo study reported that MCT and MCT/
soybean oil LEs were both associated with impaired
neutrophil killing of Candida albicans [59]. An in vitro
study showed that a MCT/soybean oil LE inhibited the
proliferation of T-lymphocytes but not lymphokine-acti-
vated killer cells [60].
There are few clinical data evaluating the effect of
MCT on immune function. In a study involving healthy
volunteers, administration of an MCT/soybean oil LE was
associated with increased total leukocyte and neutrophil
counts and signiﬁcantly decreased lymphocyte counts
[61]. A second study of healthy subjects found that, in
contrast to intermittent infusion of soybean-oil-based LE,
Table 3 Diseases and intensive care unit states associated with
reactive oxygen species-mediated tissue damage [39]
Septic shock
Acute respiratory distress syndrome
Systemic inﬂammatory response syndrome
Disseminated intravascular coagulation
Multiple organ dysfunction
Burns
Cardiovascular disease
Diabetes mellitus
Trauma
Reperfusion injury
Cancer
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a
l
i
p
i
d
v
s
.
L
i
p
o
f
u
n
d
i
n
M
C
T
?
a
-
t
o
c
o
p
h
e
r
o
l
(
2
0
0
m
g
/
d
L
)
f
o
r
1
1
d
a
y
s
S
e
r
u
m
c
o
n
c
e
n
t
r
a
t
i
o
n
s
o
f
a
-
t
o
c
o
p
h
e
r
o
l
a
t
d
a
y
1
1
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
h
i
g
h
e
r
f
o
r
L
i
p
o
f
u
n
d
i
n
M
C
T
v
s
.
I
n
t
r
a
l
i
p
i
d
(
P
=
0
.
0
0
6
)
M
a
l
o
n
d
i
a
l
d
e
h
y
d
e
/
m
g
L
D
L
-
a
n
d
V
L
D
L
-
c
h
o
l
e
s
t
e
r
o
l
a
t
d
a
y
1
1
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
r
e
d
u
c
e
d
f
o
r
L
i
p
o
f
u
n
d
i
n
M
C
T
v
s
.
I
n
t
r
a
l
i
p
i
d
(
P
=
0
.
0
2
2
)
I
m
m
u
n
o
s
u
p
p
r
e
s
s
i
o
n
/
i
n
f
e
c
t
i
o
n
r
a
t
e
s
B
a
t
t
i
s
t
e
l
l
a
e
t
a
l
.
[
5
3
]
A
d
u
l
t
t
r
a
u
m
a
p
a
t
i
e
n
t
s
(
N
=
6
0
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
t
r
i
a
l
I
n
t
r
a
l
i
p
i
d
v
s
.
P
N
c
o
n
t
a
i
n
i
n
g
n
o
l
i
p
i
d
s
f
o
r
1
0
d
a
y
s
M
e
a
n
d
u
r
a
t
i
o
n
o
f
m
e
c
h
a
n
i
c
a
l
v
e
n
t
i
l
a
t
i
o
n
:
2
7
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
5
d
a
y
s
(
n
o
l
i
p
i
d
s
;
P
=
0
.
0
1
)
M
e
a
n
I
C
U
s
t
a
y
:
2
9
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
8
d
a
y
s
(
n
o
l
i
p
i
d
s
;
P
=
0
.
0
2
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
3
9
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
2
7
d
a
y
s
(
n
o
l
i
p
i
d
s
;
P
=
0
.
0
3
)
T
o
t
a
l
n
u
m
b
e
r
o
f
i
n
f
e
c
t
i
o
u
s
c
o
m
p
l
i
c
a
t
i
o
n
s
:
7
2
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
3
9
(
n
o
l
i
p
i
d
s
;
P
\
0
.
0
5
)
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
w
i
t
h
p
n
e
u
m
o
n
i
a
:
2
2
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
3
(
n
o
l
i
p
i
d
s
;
P
=
0
.
0
5
)
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
w
i
t
h
s
e
p
s
i
s
:
1
3
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
5
(
n
o
l
i
p
i
d
s
;
P
=
0
.
0
4
)
W
e
i
s
s
e
t
a
l
.
[
5
5
]
A
d
u
l
t
s
u
n
d
e
r
g
o
i
n
g
a
b
d
o
m
i
n
a
l
s
u
r
g
e
r
y
(
N
=
2
4
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
t
r
i
a
l
L
i
p
o
v
e
n
?
O
m
e
g
a
v
e
n
v
s
.
L
i
p
o
v
e
n
f
o
r
5
d
a
y
s
M
e
a
n
I
C
U
s
t
a
y
:
4
.
1
(
L
i
p
o
v
e
n
?
O
m
e
g
a
v
e
n
)
v
s
.
9
.
1
d
a
y
s
(
L
i
p
o
v
e
n
;
N
S
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
1
7
.
8
(
L
i
p
o
v
e
n
?
O
m
e
g
a
v
e
n
)
v
s
.
2
3
.
5
d
a
y
s
(
L
i
p
o
v
e
n
;
N
S
)
N
u
m
b
e
r
o
f
i
n
f
e
c
t
i
o
u
s
c
o
m
p
l
i
c
a
t
i
o
n
s
:
5
i
n
e
a
c
h
g
r
o
u
p
G
r
a
u
e
t
a
l
.
[
6
4
]
A
d
u
l
t
s
u
n
d
e
r
g
o
i
n
g
l
a
p
a
r
o
t
o
m
y
(
N
=
7
2
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
t
r
i
a
l
I
n
t
r
a
l
i
p
i
d
v
s
.
L
i
p
o
f
u
n
d
i
n
-
M
C
T
I
n
c
i
d
e
n
c
e
o
f
i
n
t
r
a
-
a
b
d
o
m
i
n
a
l
a
b
s
c
e
s
s
e
s
:
3
2
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
8
%
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
;
P
\
0
.
0
5
)
I
n
c
i
d
e
n
c
e
o
f
i
n
-
h
o
s
p
i
t
a
l
m
o
r
t
a
l
i
t
y
:
3
6
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
5
%
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
;
N
S
)
G
a
r
c
i
a
-
d
e
-
L
o
r
e
n
z
o
e
t
a
l
.
[
3
1
]
A
d
u
l
t
s
w
i
t
h
s
e
v
e
r
e
b
u
r
n
s
(
N
=
2
2
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
d
t
r
i
a
l
C
l
i
n
O
l
e
i
c
v
s
.
L
i
p
o
f
u
n
d
i
n
-
M
C
T
f
o
r
6
d
a
y
s
M
e
a
n
I
C
U
s
t
a
y
:
3
2
.
9
(
C
l
i
n
O
l
e
i
c
)
v
s
.
4
1
.
8
d
a
y
s
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
;
N
S
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
5
7
.
0
(
C
l
i
n
O
l
e
i
c
)
v
s
.
6
4
.
9
d
a
y
s
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
i
n
f
e
c
t
i
o
n
s
:
6
p
a
t
i
e
n
t
s
i
n
e
a
c
h
g
r
o
u
p
I
n
c
i
d
e
n
c
e
o
f
i
n
-
I
C
U
m
o
r
t
a
l
i
t
y
:
3
6
%
(
C
l
i
n
O
l
e
i
c
)
v
s
.
2
7
%
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
)
740T
a
b
l
e
4
c
o
n
t
i
n
u
e
d
C
l
i
n
i
c
a
l
s
t
u
d
y
P
o
p
u
l
a
t
i
o
n
D
e
s
i
g
n
T
r
e
a
t
m
e
n
t
g
r
o
u
p
s
K
e
y
ﬁ
n
d
i
n
g
s
H
u
s
c
h
a
k
e
t
a
l
.
[
8
8
]
A
d
u
l
t
m
u
l
t
i
p
l
e
t
r
a
u
m
a
p
a
t
i
e
n
t
s
(
N
=
3
3
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
o
p
e
n
-
l
a
b
e
l
s
t
u
d
y
C
l
i
n
O
l
e
i
c
(
l
i
p
i
d
-
t
o
-
g
l
u
c
o
s
e
r
a
t
i
o
=
3
:
1
)
v
s
.
L
i
p
o
f
u
n
d
i
n
-
M
C
T
(
l
i
p
i
d
-
t
o
-
g
l
u
c
o
s
e
r
a
t
i
o
=
1
:
3
)
f
o
r
6
d
a
y
s
M
e
a
n
d
u
r
a
t
i
o
n
o
f
m
e
c
h
a
n
i
c
a
l
v
e
n
t
i
l
a
t
i
o
n
:
1
3
(
C
l
i
n
O
l
e
i
c
/
l
o
w
g
l
u
c
o
s
e
)
v
s
.
2
4
d
a
y
s
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
/
h
i
g
h
g
l
u
c
o
s
e
;
P
=
0
.
0
1
)
M
e
a
n
I
C
U
s
t
a
y
:
1
8
(
C
l
i
n
O
l
e
i
c
/
l
o
w
g
l
u
c
o
s
e
)
v
s
.
2
5
d
a
y
s
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
/
h
i
g
h
g
l
u
c
o
s
e
;
P
=
0
.
0
4
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
8
0
(
C
l
i
n
O
l
e
i
c
/
l
o
w
g
l
u
c
o
s
e
)
v
s
.
8
5
d
a
y
s
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
/
h
i
g
h
g
l
u
c
o
s
e
;
N
S
)
M
e
a
n
s
e
p
s
i
s
s
c
o
r
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
l
o
w
e
r
f
o
r
C
l
i
n
O
l
e
i
c
/
l
o
w
g
l
u
c
o
s
e
v
s
.
L
i
p
o
f
u
n
d
i
n
-
M
C
T
/
h
i
g
h
g
l
u
c
o
s
e
o
n
d
a
y
s
5
–
1
4
(
P
\
0
.
0
5
)
W
i
c
h
m
a
n
n
e
t
a
l
.
[
7
0
]
A
d
u
l
t
s
u
n
d
e
r
g
o
i
n
g
a
b
d
o
m
i
n
a
l
s
u
r
g
e
r
y
(
N
=
2
5
6
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
s
t
u
d
y
I
n
t
r
a
l
i
p
i
d
v
s
.
L
i
p
o
p
l
u
s
f
o
r
5
d
a
y
s
M
e
a
n
I
C
U
s
t
a
y
:
6
.
3
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
4
.
1
d
a
y
s
(
L
i
p
o
p
l
u
s
;
N
S
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
2
1
.
9
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
7
.
2
d
a
y
s
(
L
i
p
o
p
l
u
s
;
P
=
0
.
0
0
6
1
)
I
n
c
i
d
e
n
c
e
o
f
p
y
r
e
x
i
a
:
2
4
.
0
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
1
7
.
3
%
(
L
i
p
o
p
l
u
s
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
c
a
t
h
e
t
e
r
-
r
e
l
a
t
e
d
s
e
p
s
i
s
:
3
.
9
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
3
.
1
%
(
L
i
p
o
p
l
u
s
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
p
n
e
u
m
o
n
i
a
:
3
.
9
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
0
.
8
%
(
L
i
p
o
p
l
u
s
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
m
o
r
t
a
l
i
t
y
:
1
.
6
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
4
.
7
%
(
L
i
p
o
p
l
u
s
;
N
S
)
M
a
t
e
u
-
d
e
A
n
t
o
n
i
o
e
t
a
l
.
[
7
4
]
A
d
u
l
t
s
r
e
q
u
i
r
i
n
g
P
N
(
N
=
4
2
)
R
e
t
r
o
s
p
e
c
t
i
v
e
,
o
b
s
e
r
v
a
t
i
o
n
a
l
s
t
u
d
y
I
n
t
r
a
l
i
p
i
d
v
s
.
C
l
i
n
O
l
e
i
c
M
e
a
n
I
C
U
s
t
a
y
:
3
1
.
3
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
2
5
.
2
d
a
y
s
(
C
l
i
n
O
l
e
i
c
;
N
S
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
4
6
.
5
(
I
n
t
r
a
l
i
p
i
d
)
v
s
4
5
.
4
d
a
y
s
(
C
l
i
n
O
l
e
i
c
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
s
e
p
s
i
s
:
5
0
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
4
3
.
5
%
(
C
l
i
n
O
l
e
i
c
;
N
S
)
I
n
c
i
d
e
n
c
e
o
f
m
o
r
t
a
l
i
t
y
:
4
4
%
(
I
n
t
r
a
l
i
p
i
d
)
v
s
.
4
7
.
8
%
(
C
l
i
n
O
l
e
i
c
;
N
S
)
H
e
l
l
e
r
e
t
a
l
.
[
5
6
]
A
d
u
l
t
s
r
e
q
u
i
r
i
n
g
t
o
t
a
l
P
N
(
N
=
6
6
1
)
P
r
o
s
p
e
c
t
i
v
e
,
o
p
e
n
-
l
a
b
e
l
s
t
u
d
y
I
n
t
r
a
l
i
p
i
d
?
O
m
e
g
a
v
e
n
f
o
r
C
3
d
a
y
s
M
e
a
n
I
C
U
s
t
a
y
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
d
e
c
r
e
a
s
e
d
a
t
O
m
e
g
a
v
e
n
d
o
s
e
s
[
0
.
0
5
g
/
k
g
p
e
r
d
a
y
(
P
\
0
.
0
0
1
)
M
e
a
n
h
o
s
p
i
t
a
l
s
t
a
y
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
d
e
c
r
e
a
s
e
d
a
t
O
m
e
g
a
v
e
n
d
o
s
e
s
[
0
.
0
5
g
/
k
g
p
e
r
d
a
y
(
P
\
0
.
0
0
1
)
R
e
q
u
i
r
e
m
e
n
t
f
o
r
a
n
t
i
b
i
o
t
i
c
s
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
h
i
g
h
e
r
a
t
O
m
e
g
a
v
e
n
d
o
s
e
s
\
0
.
0
5
v
s
.
0
.
1
5
–
0
.
2
g
/
k
g
p
e
r
d
a
y
(
P
\
0
.
0
0
1
)
S
u
r
v
i
v
a
l
r
a
t
e
:
s
i
g
n
i
ﬁ
c
a
n
t
l
y
l
o
w
e
r
a
t
O
m
e
g
a
v
e
n
d
o
s
e
s
\
0
.
0
5
v
s
.
0
.
1
–
0
.
2
g
/
k
g
p
e
r
d
a
y
(
P
\
0
.
0
0
1
)
I
n
ﬂ
a
m
m
a
t
i
o
n
G
o
g
o
s
e
t
a
l
.
[
6
8
]
S
e
v
e
r
e
l
y
i
l
l
a
d
u
l
t
s
(
N
=
2
0
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
s
t
u
d
y
L
i
p
o
f
u
n
d
i
n
-
S
v
s
.
L
i
p
o
f
u
n
d
i
n
-
M
C
T
f
o
r
3
0
d
a
y
s
C
i
r
c
u
l
a
t
i
n
g
T
N
F
-
a
c
o
n
c
e
n
t
r
a
t
i
o
n
s
:
n
o
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
g
r
o
u
p
s
E
n
d
o
t
o
x
i
n
-
i
n
d
u
c
e
d
T
N
F
-
a
r
e
l
e
a
s
e
a
t
d
a
y
3
0
v
s
.
b
a
s
e
l
i
n
e
:
1
8
5
.
4
v
s
.
9
5
.
3
p
g
/
m
L
(
L
i
p
o
f
u
n
d
i
n
-
S
;
P
\
0
.
0
1
)
;
9
0
.
7
v
s
.
1
0
3
.
8
p
g
/
m
L
(
L
i
p
o
f
u
n
d
i
n
-
M
C
T
;
N
S
)
741T
a
b
l
e
4
c
o
n
t
i
n
u
e
d
C
l
i
n
i
c
a
l
s
t
u
d
y
P
o
p
u
l
a
t
i
o
n
D
e
s
i
g
n
T
r
e
a
t
m
e
n
t
g
r
o
u
p
s
K
e
y
ﬁ
n
d
i
n
g
s
K
o
l
l
e
r
e
t
a
l
.
[
7
1
]
A
d
u
l
t
s
u
n
d
e
r
g
o
i
n
g
a
b
d
o
m
i
n
a
l
s
u
r
g
e
r
y
(
N
=
3
0
)
P
r
o
s
p
e
c
t
i
v
e
,
r
a
n
d
o
m
i
z
e
d
,
d
o
u
b
l
e
-
b
l
i
n
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742infusion of PN containing MCT/soybean oil LE did not
impair the clearance of 99Tc-sulfur colloid by the retic-
uloendothelial system [62]. In pediatric surgical patients
receiving PN, an MCT/soybean oil LE was associated
with a signiﬁcantly increased lymphocyte count when
compared with a soybean-oil-based LE [63]. Another
study compared an MCT/soybean oil LE with a soybean-
oil-based LE in severely undernourished patients under-
going laparotomy [64]. In that study, the incidence of
intra-abdominal abscesses was signiﬁcantly lower in the
MCT/soybean oil group than the soybean oil group, but
there were no signiﬁcant differences between the groups
for other infections (Table 4)[ 64].
Lipid emulsions containing high concentrations of
olive oil may have less impact on the host immune
response than soybean-oil-based or MCT/soybean oil
LEs, with little effect on lymphocytes, natural killer cells,
and neutrophils. In an in vitro study, the percentage of
lymphocytes undergoing apoptosis or necrosis was higher
following incubation with 200 lM LA (77%) than with
200 lM OA (23%); both were higher than the control
group (3%) [65]. Another study showed that lymphocyte
activation was dose-dependently inhibited by soybean-
oil-based LEs but not an olive-oil-rich LE [66]. In con-
trast to a MCT/soybean oil LE, an olive-oil-rich LE
had little effect on neutrophil activation, phagocytosis,
generation of ROS or chemotaxis [67]. The immunosup-
portive effects of an olive-oil-rich emulsion may be
reﬂected clinically by the low incidence of infectious
complications reported in severely burned patients
receiving PN in the ICU: in a study evaluating this patient
population, the incidences of sepsis and multiple organ
failure and the duration of mechanical ventilation, ICU
stay, and hospital stay were comparable for patients
receiving olive-oil-rich and MCT/soybean oil LEs
(Table 4)[ 31].
Inﬂammation
Administration of soybean-oil-based LEs is associated
with high blood levels of the x-6 PUFA LA and its
metabolite AA, the further metabolism of which may
produce proinﬂammatory eicosanoids [e.g., prostaglan-
dins, thromboxanes, and leukotrienes (LT)] that can
regulate additional inﬂammatory mediators [e.g., tumor
necrosis factor (TNF)-a][ 32]. This hypothesis is sup-
ported by a study reporting that malnourished, severely ill
patients experienced signiﬁcantly increased total produc-
tion of TNF-a when receiving PN with a soybean-oil-
based LE but not an MCT/soybean oil LE [68]. Although
there has been much focus on the proinﬂammatory effects
of AA-derived eicosanoids, lipoxins derived from AA
have potent inﬂammation-resolving effects [69].
Conversely, the long-chain x-3 PUFAs EPA and DHA
found in ﬁsh oils are thought to possess anti-inﬂammatory
properties because they are readily incorporated into cell
membranes and thereby impact AA metabolism [18, 32],
because the metabolism of EPA is associated with pro-
duction of less biologically potent eicosanoids than those
produced from AA [18, 32], and because EPA and DHA
are precursors of resolvins with powerful inﬂammation-
resolving properties [18, 69]. Indeed, when soybean oil
was partially replaced with ﬁsh oil (3:1 ratio) in surgical
patients receiving PN, LT synthesis was shifted from the
proinﬂammatory LTB4 (produced from AA) to the less
potent LTB5 (produced from EPA) (Table 4)[ 70, 71].
This change was associated with signiﬁcantly reduced
concentrations of the inﬂammatory mediators interleukin
(IL)-6 and TNF-a [72]. In patients with sepsis, concen-
trations of IL-1b, IL-6, IL-8, and TNF-a released from
mononuclear leukocytes were signiﬁcantly increased
following administration of a soybean-oil-based LE
compared with a decrease of approximately 30% fol-
lowing administration of a ﬁsh-oil-based LE [73].
Lipid emulsions rich in olive oil have not been well
studied with regard to their effect on inﬂammation;
however, a few studies have demonstrated that OA has
relatively few effects on the production of inﬂammatory
mediators. In a preclinical study, lipopolysaccharide-
induced production of IL-1b, IL-6, IL-8, and TNF-a by
neutrophils was not altered by an olive-oil-rich LE,
compared with signiﬁcant reductions in IL-1b with soy-
bean-oil-based and MCT/soybean oil LEs [67]. In another
study, infectious complication rates, mortality rates, and
length of ICU stay were similar among critically ill
patients receiving PN containing soybean-oil-based and
olive-oil-rich LEs [74].
Thrombosis
Thrombosis is a common and serious complication for
many critically ill, surgical, and trauma patients, as these
states may be associated with changes in the availability
of clotting factors and alterations in the ﬁbrinolytic
pathway, resulting in intravascular coagulation [75].
However, the effects of LEs on coagulation have not been
extensively assessed. In one study, platelet aggregation
was inhibited immediately following intravenous infusion
of a ﬁsh-oil-based LE to healthy volunteers, but had
returned to normal at 24 h [76]. In surgical patients
receiving PN, the latency to collagen-induced platelet
aggregation and time to maximal platelet aggregation
were signiﬁcantly longer for a soybean-oil-based LE than
for a ﬁsh-oil-enriched LE; however, adenosine-dipho-
sphate-induced platelet aggregation and bleeding time
were unchanged [77]. Another study found no change in
platelet aggregation for critically ill patients receiving
either soybean-oil-based or MCT/soybean oil LEs [78].
The effects of parenteral olive-oil-rich LEs on
thrombosis have not been systematically evaluated.
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744However, in one study of patients undergoing hemodial-
ysis, the need to change hemoﬁlters due to blood
coagulation was signiﬁcantly reduced among patients
receiving PN containing an olive-oil-rich LE compared
with a soybean-oil-based LE [79].
Choosing a parenteral lipid emulsion for the critically
ill patient
Components of commercially available lipid
emulsions
A summary of the key characteristics of available par-
enteral LEs is presented in Table 5; in some countries
(i.e., the USA) only soybean-oil-based LEs are available
[8]. The choice of parenteral LE should be based upon
several considerations. It has been suggested that the ratio
of LA to ALA is important because of competition
between these FA for a number of enzymes, thereby
potentially inﬂuencing the production of eicosanoid and
eicosanoid-like inﬂammatory mediators [80]. However, a
number of studies have suggested that the absolute con-
centrations of certain PUFA are more important than their
ratio in determining their biologic effects [80, 81]. In
addition, the FA content of LEs can vary depending upon
the speciﬁc source of oil (e.g., EPA and DHA within
different ﬁsh oils) [80].
The stability of LEs, with respect to phase separation
and presence of large globules, is also an important issue
in clinical settings in which the ﬁnal concentrations of
lipid components and emulsiﬁers are of key importance.
All LEs eventually become unstable when diluted above a
certain threshold within the PN formulation. Current
regulations in the USA require that globules [5 lmd o
not exceed 0.05% (weight/volume) of the emulsion [82].
In general, MCT/soybean oil and olive-oil-rich LEs have
demonstrated greater stability when compared with soy-
bean-oil- and safﬂower-oil-based LEs, although stability
may vary between manufacturers [82, 83]. The stability of
MCT/soybean oil LEs may be due to the inclusion of
shorter-chain lipids, which exhibit a lower free energy
when dispersed in water, resulting in greater miscibility
between phases and reduced physicochemical stress on
emulsifying agents compared with LEs containing pre-
dominantly longer-chain triglycerides [83]. Olive-oil-rich
LEs contain sodium oleate, which acts as an additional
emulsifying agent and thereby augments stability [83]. In
addition, the stability of PN formulations that contain LEs
may be affected by interactions between FA and other
commonly administered compounds, such as carnitine,
heparin, and some vitamins [84–86].
Potential therapeutic roles for lipid emulsions
Lipid emulsions demonstrate different biologic effects
depending upon their speciﬁc FA content, which may
translate into beneﬁcial effects for selected patients
(Table 6). The biologic effects associated with LEs are
likely to beneﬁt a majority of patients receiving parenteral
LEs, including those on long-term total PN, but may have
the greatest importance for patients under metabolic
stress. Therefore, physicians need to consider several
issues when selecting an LE as part of a PN regimen.
All currently available LEs provide sufﬁcient x-6 and
x-3 EFA, with the exception of 100% ﬁsh oil LE, which
should generally only be used as a pharmacological agent
or as a supplement to other LEs [21, 22]. Although there
are conﬂicting views regarding the comparative utility of
different LE formulations in critically ill patients, there is
growing consensus that LEs based entirely on soybean oil
should be avoided in favor of emulsions in which the LA
and ALA content is partially replaced by MCT, olive oil
providing MUFA or ﬁsh oil providing EPA and DHA.
This is particularly true for patients with highly proin-
ﬂammatory states, such as surgical, trauma, burn, and
septic patients [8, 87]. In addition, the clinical use of LEs
should not exacerbate oxidative stress in critically ill
patients. Unfortunately, evidence on the differential
effects of LEs in critically ill patients remains limited.
Furthermore, inconsistencies of ﬁndings between studies
have suggested that the biologic effects of FA may vary
with the medical condition and level of metabolic stress;
therefore, further clinical trials exploring the effects of FA
in different subpopulations of critically ill patients are
highly desirable.
Table 6 Potential therapeutic
applications of lipid emulsions Cell function and proliferation
Provide sufﬁcient fatty acids
Improve metabolism and limit/reverse energy deﬁcit
Oxidative stress
Limit the contribution of lipid peroxidation to oxidative stress
Maintain or increase antioxidant concentrations
Intrinsic immune function
Support the immune system and limit immunosuppression
Reduce the incidence of infectious complications
Inﬂammation
Prevent/regulate hyperinﬂammation, especially important for patients with pre-existing
inﬂammation (e.g., surgery, sepsis, chronic inﬂammatory diseases)
745Conclusions
Energy deﬁcit is a major problem among ICU patients
and is associated with an increased incidence of compli-
cations, length of stay, and mortality. PN, either alone or
in combination with EN, can improve caloric delivery to
critically ill patients, preventing or correcting energy
deﬁcits and improving outcomes. Lipids are an important
source of calories in artiﬁcial nutrition, and they have
demonstrated a wide range of biologic activities that may
beneﬁt a variety of patients receiving PN, as well as those
receiving EN with or without PN supplementation.
Parenteral lipid emulsions derived from soybean oil
are the most extensively evaluated formulations in pre-
clinical and clinical studies and have demonstrated
efﬁcacy and safety in delivering vital nutrition to criti-
cally ill patients. Newer LEs that utilize partial
substitution of soybean oil with MCT, olive oil or ﬁsh oil
either alone or in combination have demonstrated poten-
tial beneﬁts in terms of reduced impacts on oxidative
stress and differential effects on cell-mediated immunity
and inﬂammation. However, few published studies have
evaluated the biologic effects of newer parenteral LEs,
and data assessing the clinical beneﬁts of these newer
formulations are limited and sometimes inconsistent
because of the heterogeneity of the study designs and
patient populations. Ongoing research to further charac-
terize and compare the biologic properties of lipids given
parenterally, as well as enterally, will be an important
resource for physicians, especially those managing
critically ill patients, who are often under metabolic
stress. These studies must be adequately designed and
well controlled. Until then, the prescription of LEs should
be based upon the limited clinical data available, the
range of available LEs, cost implications, and an under-
standing of the potential biologic effects of their
components, bearing in mind the situation and therapeutic
goals of the individual patient.
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